This highlights the pivotal role of mTOR in the pathogenesis of ME/CFS.<h4>Methods</h4>We conducted a decentralized, uncontrolled trial of rapamycin in 86 patients with ME/CFS to evaluate its safety and efficacy. Here, MTOR is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.